We have two oncology conversations for you today. The first is with Dr. Saroj Niraula of the University of Manitoba, and together we discuss the necessity of randomized controlled trials for granting FDA approval of cancer drugs. The second is with Dr. Ghulam Rehman "Manni" Mohyuddin of the University of Utah on a variety of myeloma studies, including LIGHTHOUSE, OCEANS, and HORIZON.

Feasibility of RCTs: doi.org/10.1093/jncics/pkab061
RR of Alternative Treatments: doi.org/10.1002/ijc.33231
Study Time Reduction: doi.org/10.1001/jamainternmed.2018.8351

Back us on Patreon! www.patreon.com/plenarysession

Check out our YouTube channel: www.youtube.com/channel/UCUibd0E2kdF9N9e-EmIbUew

4.17 RCTs for Cancer Drug Approval with Dr. Saroj Niraula & Myeloma Studies with Dr. Manni Mohyuddin

A podcast on medicine, oncology, & health policy. 
Host: Vinay Prasad, MD MPH from University of California San Francisco.
Tweet your feedback to @Plenary_Session or e-mail plenarysessionpodcast@gmail.com

Science & Medicine

Natural Sciences

Social Sciences

Medicine

Patient advocates, Pharma funding, and is MRD a suitable endpoint

Patient advocates funded by Pharma

FDA makes MRD the basis for AA

Another flawed quality metric. Reviewing the NEJM paper "Beta-Blockers After Myocardial Infarction and Preserved Ejection Fraction".

4.17 RCTs for Cancer Drug Approval with Dr. Saroj Niraula & Myeloma Studies with Dr. Manni Mohyuddin

Download our free app to listen on your phone